SOLNATIDE project iconRTDS

The SOLNATIDE project

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new Coronavirus

 

SOLNATIDE project logo

 

The Challenge

Patients infected with the new Coronavirus (2019-nCoV, Covid-19) suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approximately 30% of Covid-2019 patients further develop life-threatening Acute Respiratory Distress Syndrome (ARDS) resulting in a very high mortality rate. To date, no medicine has been approved for the therapeutic treatment of Pulmonary Permeability Oedema and ARDS.

 

The Solution

The SOLNATIDE project will clinically test peptide-based products targeting life-threatening pulmonary diseases (e.g. oedematous respiratory failure, acute lung injury). APEPTICO’s lead-compound Solnatide (IMP) has been designed for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of Pulmonary Oedema (PPO).

 

The new Coronavirus ((c) Shutterstock no. 1643947495 for RTDS)

 

Orally inhaled Solnatide has delivered clinical proof-of-concept in one Phase I and two Phase II clinical studies (EUDRACT No. 2011-000223-33, 2012-001863-64, 2013-000716-21). Currently, Solnatide is subject to a Phase IIB trial (EUDRACT No. 2017-003855-47) with clinical trials approved by competent authorities and ethics committees in Germany and Austria.  The SOLNATIDE project will generate clinical trial results assessing safety, tolerability and clinical efficacy of Solnatide IMP in Covid-19 patients.

 

The SOLNATIDE project in a nutshell

Funding: €1.626 million

Funding: European Commission (EC) call “H2020-SC1-PHE-CORONAVIRUS-2020” (grant no. 101003595)

Project start: April 1st 2020

Duration: 21 months

Consortium: 5 partners from Austria, Germany, Italy and Spain:

RTDS Association, AT – Coordinator, Project & Communication Management

APEPTICO Forschung und Entwicklungs GmbH, AT – Scientific coordinator

BCN Peptides SA, ES

Ludwig-Maximilians-University Munich (LMU) University Hospital, GER

OPIS SRL, IT

 

 

Contact: RTDS Association, Dr. Natascha Miljkovic, solnatide (a) rtds-group.com, +43-(0)1-3231000-11, Lerchengasse 25/2-3, A-1080 Vienna, Austria.

 

Further information on SOLNATIDE project

Currently, we are preparing information to be shared on a joint website representing all 18 EU Emergency Projects (to be established soon). Stay tuned for updates!

 

SOLNATIDE social media channels are:

SOLNATIDE  project LinkedIn showcase page

SOLNATIDE project on ResearchGate

SOLNATIDE on Twitter

 

Other sources are:

European Commission call

First public announcement by the EC

Announcement on EU Cordis platform

Download the SOLNATIDE project factsheet (April 2020)